The effect of the UGT1A1∗28 allele on survival after irinotecan-based chemotherapy: A collaborative meta-analysis

M. M. Dias, J. P. Pignon, C. S. Karapetis, V. Boige, B. Glimelius, D. M. Kweekel, Primo N Lara, P. Laurent-Puig, E. Martinez-Balibrea, D. Páez, C. J A Punt, M. W. Redman, G. Toffoli, M. Wadelius, R. A. Mckinnon, M. J. Sorich

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

To date, studies of irinotecan pharmacogenetics have mostly focused on the effect of the UGT1A1∗28 allele on irinotecan-related toxicity. However, the clinical utility of routine UGT1A1∗28 genotyping to pre-emptively adjust irinotecan dosage is dependent upon whether UGT1A1∗28 also affects patient survival following irinotecan therapy. Previous observational studies evaluating the influence of UGT1A1∗28 on survival have shown contradictory results. A systematic review and meta-analysis of both published and unpublished data were performed to summarize the available evidence of the relationship between the UGT1A1∗28 allele and patient survival related to irinotecan therapy. Overall and progression-free survival meta-analysis data were available for 1524 patients and 1494 patients, respectively. The difference in the survival between patients of different UGT1A1∗28 genotypes (homozygous, heterozygous or wild-type) who had received irinotecan was not found to be statistically significant. There was also no evidence of irinotecan dose, regimen or line of therapy having an impact on this association.

Original languageEnglish (US)
Pages (from-to)424-431
Number of pages8
JournalPharmacogenomics Journal
Volume14
Issue number5
DOIs
StatePublished - Oct 11 2014

Fingerprint

irinotecan
Meta-Analysis
Alleles
Drug Therapy
Survival
Survival Analysis
Disease-Free Survival
Observational Studies

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Dias, M. M., Pignon, J. P., Karapetis, C. S., Boige, V., Glimelius, B., Kweekel, D. M., ... Sorich, M. J. (2014). The effect of the UGT1A1∗28 allele on survival after irinotecan-based chemotherapy: A collaborative meta-analysis. Pharmacogenomics Journal, 14(5), 424-431. https://doi.org/10.1038/tpj.2014.16

The effect of the UGT1A1∗28 allele on survival after irinotecan-based chemotherapy : A collaborative meta-analysis. / Dias, M. M.; Pignon, J. P.; Karapetis, C. S.; Boige, V.; Glimelius, B.; Kweekel, D. M.; Lara, Primo N; Laurent-Puig, P.; Martinez-Balibrea, E.; Páez, D.; Punt, C. J A; Redman, M. W.; Toffoli, G.; Wadelius, M.; Mckinnon, R. A.; Sorich, M. J.

In: Pharmacogenomics Journal, Vol. 14, No. 5, 11.10.2014, p. 424-431.

Research output: Contribution to journalArticle

Dias, MM, Pignon, JP, Karapetis, CS, Boige, V, Glimelius, B, Kweekel, DM, Lara, PN, Laurent-Puig, P, Martinez-Balibrea, E, Páez, D, Punt, CJA, Redman, MW, Toffoli, G, Wadelius, M, Mckinnon, RA & Sorich, MJ 2014, 'The effect of the UGT1A1∗28 allele on survival after irinotecan-based chemotherapy: A collaborative meta-analysis', Pharmacogenomics Journal, vol. 14, no. 5, pp. 424-431. https://doi.org/10.1038/tpj.2014.16
Dias, M. M. ; Pignon, J. P. ; Karapetis, C. S. ; Boige, V. ; Glimelius, B. ; Kweekel, D. M. ; Lara, Primo N ; Laurent-Puig, P. ; Martinez-Balibrea, E. ; Páez, D. ; Punt, C. J A ; Redman, M. W. ; Toffoli, G. ; Wadelius, M. ; Mckinnon, R. A. ; Sorich, M. J. / The effect of the UGT1A1∗28 allele on survival after irinotecan-based chemotherapy : A collaborative meta-analysis. In: Pharmacogenomics Journal. 2014 ; Vol. 14, No. 5. pp. 424-431.
@article{f5163b3ffbfa4a769da5de00e3666b69,
title = "The effect of the UGT1A1∗28 allele on survival after irinotecan-based chemotherapy: A collaborative meta-analysis",
abstract = "To date, studies of irinotecan pharmacogenetics have mostly focused on the effect of the UGT1A1∗28 allele on irinotecan-related toxicity. However, the clinical utility of routine UGT1A1∗28 genotyping to pre-emptively adjust irinotecan dosage is dependent upon whether UGT1A1∗28 also affects patient survival following irinotecan therapy. Previous observational studies evaluating the influence of UGT1A1∗28 on survival have shown contradictory results. A systematic review and meta-analysis of both published and unpublished data were performed to summarize the available evidence of the relationship between the UGT1A1∗28 allele and patient survival related to irinotecan therapy. Overall and progression-free survival meta-analysis data were available for 1524 patients and 1494 patients, respectively. The difference in the survival between patients of different UGT1A1∗28 genotypes (homozygous, heterozygous or wild-type) who had received irinotecan was not found to be statistically significant. There was also no evidence of irinotecan dose, regimen or line of therapy having an impact on this association.",
author = "Dias, {M. M.} and Pignon, {J. P.} and Karapetis, {C. S.} and V. Boige and B. Glimelius and Kweekel, {D. M.} and Lara, {Primo N} and P. Laurent-Puig and E. Martinez-Balibrea and D. P{\'a}ez and Punt, {C. J A} and Redman, {M. W.} and G. Toffoli and M. Wadelius and Mckinnon, {R. A.} and Sorich, {M. J.}",
year = "2014",
month = "10",
day = "11",
doi = "10.1038/tpj.2014.16",
language = "English (US)",
volume = "14",
pages = "424--431",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - The effect of the UGT1A1∗28 allele on survival after irinotecan-based chemotherapy

T2 - A collaborative meta-analysis

AU - Dias, M. M.

AU - Pignon, J. P.

AU - Karapetis, C. S.

AU - Boige, V.

AU - Glimelius, B.

AU - Kweekel, D. M.

AU - Lara, Primo N

AU - Laurent-Puig, P.

AU - Martinez-Balibrea, E.

AU - Páez, D.

AU - Punt, C. J A

AU - Redman, M. W.

AU - Toffoli, G.

AU - Wadelius, M.

AU - Mckinnon, R. A.

AU - Sorich, M. J.

PY - 2014/10/11

Y1 - 2014/10/11

N2 - To date, studies of irinotecan pharmacogenetics have mostly focused on the effect of the UGT1A1∗28 allele on irinotecan-related toxicity. However, the clinical utility of routine UGT1A1∗28 genotyping to pre-emptively adjust irinotecan dosage is dependent upon whether UGT1A1∗28 also affects patient survival following irinotecan therapy. Previous observational studies evaluating the influence of UGT1A1∗28 on survival have shown contradictory results. A systematic review and meta-analysis of both published and unpublished data were performed to summarize the available evidence of the relationship between the UGT1A1∗28 allele and patient survival related to irinotecan therapy. Overall and progression-free survival meta-analysis data were available for 1524 patients and 1494 patients, respectively. The difference in the survival between patients of different UGT1A1∗28 genotypes (homozygous, heterozygous or wild-type) who had received irinotecan was not found to be statistically significant. There was also no evidence of irinotecan dose, regimen or line of therapy having an impact on this association.

AB - To date, studies of irinotecan pharmacogenetics have mostly focused on the effect of the UGT1A1∗28 allele on irinotecan-related toxicity. However, the clinical utility of routine UGT1A1∗28 genotyping to pre-emptively adjust irinotecan dosage is dependent upon whether UGT1A1∗28 also affects patient survival following irinotecan therapy. Previous observational studies evaluating the influence of UGT1A1∗28 on survival have shown contradictory results. A systematic review and meta-analysis of both published and unpublished data were performed to summarize the available evidence of the relationship between the UGT1A1∗28 allele and patient survival related to irinotecan therapy. Overall and progression-free survival meta-analysis data were available for 1524 patients and 1494 patients, respectively. The difference in the survival between patients of different UGT1A1∗28 genotypes (homozygous, heterozygous or wild-type) who had received irinotecan was not found to be statistically significant. There was also no evidence of irinotecan dose, regimen or line of therapy having an impact on this association.

UR - http://www.scopus.com/inward/record.url?scp=84927175471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927175471&partnerID=8YFLogxK

U2 - 10.1038/tpj.2014.16

DO - 10.1038/tpj.2014.16

M3 - Article

C2 - 24709690

AN - SCOPUS:84927175471

VL - 14

SP - 424

EP - 431

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 5

ER -